Product
CTL 19
1 clinical trial
1 indication
Indication
Hematologic DiseaseClinical trial
A Phase 1 Dose-escalation Study Testing the Feasibility and the Tolerance of Infusion of a Specific Third Party Suicide Gene-transduced Anti-HLA-DPB1*0401 CD4+ T Cell Clone in HLA-DPB1*04:01 Positive Tumor Recipients Receiving an Allotransplant From a HLA-DPB1*04:01 Negative Donor.Status: Recruiting, Estimated PCD: 2025-02-01